Clinical Trials Logo

Filter by:
NCT ID: NCT00163319 Completed - Asthma Clinical Trials

Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function, symptoms, use of rescue medication, and occurrence of side effects (such as candidiasis, hoarseness) in adults with persistent asthma. Ciclesonide will be inhaled twice daily at one dose level; fluticasone propionate will be inhaled twice daily at one dose level. The study duration consists of a baseline period (2 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.

NCT ID: NCT00163163 Completed - Clinical trials for Hypercholesterolaemia

Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women

Start date: January 2003
Phase: Phase 3
Study type: Interventional

To evaluate the effect of atorvastatin 80 mg, versus placebo, given for 12 months on carotid intima-media thickness in postmenopausal women with moderate hypercholesterolemia.

NCT ID: NCT00162266 Completed - Clinical trials for Rheumatoid Arthritis

Abatacept With Methotrexate- Phase IIB

Start date: October 2000
Phase: Phase 2
Study type: Interventional

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

NCT ID: NCT00162123 Completed - Melanoma Clinical Trials

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.

NCT ID: NCT00161954 Completed - Clinical trials for Encephalitis, Tick-borne

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Start date: March 2004
Phase: Phase 4
Study type: Interventional

The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.

NCT ID: NCT00161616 Completed - Tibial Fractures Clinical Trials

Study Evaluating InductOs in Diaphyseal Tibia Fractures

Start date: September 2003
Phase: Phase 4
Study type: Interventional

Demonstrate a larger proportion of subjects with healed fractures among subjects treated with InductOs and reamed, locked intramedullary nailing compared to subjects treated with reamed, locked intramedullary nailing alone.

NCT ID: NCT00160706 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

PRECiSE 4
Start date: February 2004
Phase: Phase 3
Study type: Interventional

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.

NCT ID: NCT00160693 Completed - Clinical trials for Rheumatoid Arthritis

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.

NCT ID: NCT00160667 Completed - Clinical trials for Neuralgia, Postherpetic

A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

Start date: October 11, 2004
Phase: Phase 2
Study type: Interventional

Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.

NCT ID: NCT00160524 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

PRECiSE 3
Start date: July 2004
Phase: Phase 3
Study type: Interventional

An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).